Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.56 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.54 |
| ▸ | MMP13 | P45452 | 1/20 | 0.52 |
| ▸ | BRD4 | O60885 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.47 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27767020 | 1.00 | MAOB (0.56) | MAOBTNKS2KCNH2CREBBPMMP13 | |
| SCHEMBL13701090 | 0.87 | KCNH2 (0.55) | MAOBTNKS2KCNH2CREBBPMMP13 | |
| SCHEMBL7193200 | 0.78 | MAPT (0.43) | MAOBLMNAMAOAGAAMAPT | |
| SCHEMBL8769357 | 0.77 | ALDH1A1 (0.63) | MAOBTNKS2MMP13TP53LMNA | |
| SCHEMBL9295153 | 0.76 | BRD4 (0.50) | CREBBPBRD4LMNAGAAMAPT | |
| SCHEMBL157619 | 0.76 | BRD4 (0.50) | CREBBPBRD4LMNAGAAMAPT | |
| SCHEMBL6247618 | 0.76 | BRD4 (0.50) | CREBBPBRD4LMNAGAAMAPT | |
| SCHEMBL27518779 | 0.75 | KCNH2 (0.55) | MAOBTNKS2KCNH2MMP13TP53 | |
| SCHEMBL14395035 | 0.75 | NPC1 (0.64) | MAOBLMNAMAOAMAPTRAB9A | |
| SCHEMBL8182443 | 0.74 | CRBN (0.67) | MAOBKCNH2MMP13TP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250302885-A1 | RHODOSPIRILLUM RUBRUM CELLS THAT LOWER PLASMA CHOLESTEROL WHILE LEAVING OTHER SERUM PROTEIN LEVELS UNAFFECTED | Curador (BE) | 2025-10-02 | — | — | US | disclosed |
| US-20240398746-A1 | FIXED DOSE COMBINATIONS AND FORMULATIONS COMPRISING ETC1002 AND EZETIMIBE AND METHODS OF TREATING OR REDUCING THE RISK OF CARDIOVASCULAR DISEASE | ESPERION THERAPEUTICS, INC. | 2024-12-05 | — | — | US | disclosed |
| EP-4461295-A2 | TRIPLET COMBINATION FORMULATIONS AND METHODS OF TREATING OR REDUCING THE RISK OF CARDIOVASCULAR DISEASE | Esperion Therapeutics, Inc. (US) | 2024-11-13 | — | — | EP | disclosed |
| US-11744816-B2 | Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease | ESPERION THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20220331373-A1 | RHODOSPIRILLUM RUBRUM CELLS THAT LOWER PLASMA CHOLESTEROL WHILE LEAVING OTHER SERUM PROTEIN LEVELS UNAFFECTED | EZCOL B.V. (NL) | 2022-10-20 | — | — | US | disclosed |
| CN-115135331-A | Rhodospirillum rubrum cells for lowering plasma cholesterol while leaving other serum protein levels unaffected | 埃兹科尔公司 | 2022-09-30 | — | — | CN | disclosed |
| CN-114099496-A | Combinations comprising ETC1002 and ezetimibe and methods of treatment | 艾斯柏伦治疗公司 | 2022-03-01 | — | — | CN | disclosed |
| EP-1362855-B1 | BETA-LACTAM COMPOUNDS, PROCESS FOR REPODUCING THE SAME AND SERUM CHOLESTEROL-LOWERING AGENTS CONTAINING THE SAME | KOTOBUKI PHARMACEUTICAL CO LTD (JP) | 2007-10-03 | — | — | EP | disclosed |
| US-7045515-B2 | β-lactam compounds process for reproducing the same and serum cholesterol-lowering agents containing the same | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2006-05-16 | — | — | US | disclosed |
| US-20040063929-A1 | Beta-lactam compounds process for reproducing the same and serum cholesterol-lowering agents containing the same | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1362855-A1 | BETA-LACTAM COMPOUNDS, PROCESS FOR REPODUCING THE SAME AND SERUM CHOLESTEROL-LOWERING AGENTS CONTAINING THE SAME | Kotobuki Pharmaceutical Co., Ltd. (JP) | 2003-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063929-A1 | Beta-lactam compounds process for reproducing the same and serum cholesterol-lowering agents containing the same | HMGCR, NCEH1, CETP | MAOB 2760/4885TNKS2 4677/4885KCNH2 1131/4885 |
| US-11744816-B2 | Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease | APOB, PCSK9, GOT2 | MAOB 762/4885TNKS2 2235/4885KCNH2 2524/4885 |
| US-20240398746-A1 | FIXED DOSE COMBINATIONS AND FORMULATIONS COMPRISING ETC1002 AND EZETIMIBE AND METHODS OF TREATING OR REDUCING THE RISK OF CARDIOVASCULAR DISEASE | APOB, PCSK9, GOT2 | MAOB 762/4885TNKS2 2235/4885KCNH2 2524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.